The treatment of the American company Eli Lilly for an early stage of Alzheimer’s disease would be rejected by the National Health Service (NHS) of Great Britain, according to the publication of the Telegraph, cited by Reuters, News.ro transmits.
The drug donanemab would be rejected by the National Institute for Health and Care Excellence (NICE), which determines which drugs are available through the NHS, the newspaper said, citing insiders.
The NHS and NICE declined to comment, and Eli Lilly did not immediately respond to a Reuters request for comment.
NICE is also unlikely to reverse its decision to reject an earlier Alzheimer’s drug, lecanemab, the article says.
Earlier this week, the Medicines and Healthcare Products Regulatory Agency (MHRA) said lecanemab’s high costs and intensive side-effect monitoring requirements made it poor value for taxpayers.
Lecanemab is the first treatment for Alzheimer’s disease licensed for use in the country, which shows some evidence that it slows the progression of the disease. Donanemab is even more effective in slowing the progression of Alzheimer’s disease and scientists have called it the “best” treatment for the disease, the Telegraph wrote.
The MHRA may not approve donanemab due to concerns about the risk of side effects, according to the report.
Both drugs have been approved for use in the United States.
A decision on donanemab has been delayed, with the regulatory body originally planning to make a decision in July, around the same time it was approved for use in the US.
Watch G4Media’s video productions below:
2024-08-25 05:05:04
#Britain #reject #treatment #early #Alzheimers #launched #company #Eli #Lilly
